|Address:||Associate Director R&D, Head of biology department
Domain Therapeutics NA Inc.
St-Laurent, Québec, CANADA
Dr. Laurent Sabbagh obtained his B.Sc. in biochemistry from McGill University. Subsequently, he obtained his M.Sc. degree in microbiology from Laval University under the supervision of Dr. Roger Levesque where he identified novel pathogenesis genes in Pseudomonas aeruginosa. He then obtained his Ph.D. in immunology from McGill University under the supervision of Dr. Rafick-Pierre Sekaly where he studied mechanisms involved in immunological memory of T lymphocytes. Following his doctoral degree Dr. Sabbagh undertook post-doctoral fellowships at the Ontario Cancer Institute and the University of Toronto where he identified novel signaling mechanisms downstream of TNF receptor family members. Dr. Sabbagh opened his laboratory in the fall of 2010 at the research centre of Maisonneuve-Rosemont Hospital where he established a research team working on the role of TNF receptors in immunological memory, inflammation and hematological malignancies. In the fall of 2013, Dr. Sabbagh pursued his research activities on inflammatory bowel disease and polycystic kidney disease at Vertex Pharmaceuticals (Canada). Subsequently between 2017 and 2020, Dr. Sabbagh led research projects aimed on drug discovery of small molecules for the treatment of inflammatory disorders and cancer at Paraza Pharma Inc. in Montreal. Since the spring of 2020, he holds the position of associate director of R&D and head of the biology department at Domain Therapeutics NA Inc.
- Neurological disorders
- Rare diseases
- Drug discovery
- Drug discovery of small molecules and antibodies for immune-oncology, neurological disorders, and rare diseases
- Regulation of tumor growth by leukocyte-specific protein 1 in T cells. Kown R, Hong BK, Lee KG, Choi E, Sabbagh L, Cho CS, Lee N, Kim WU. J Immunother Cancer. 2020 Oct;8(2):e001180.
- Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. Gavegnano C, Brehm JH, Dupuy FP, Talla A, Ribeiro SP, Kulpa DA, Cameron C, Santos S, Hurwitz SJ, Marconi VC, Routy JP, Sabbagh L, Schinazi RF, Sékaly RP. PLoS Pathog. 2017 Dec 21;13(12):e1006740.
- VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation. Oussa NA, Dahmani A, Gomis M, Richaud M, Andreev E, Navab-Daneshmand AR, Taillefer J, Carli C, Boulet S, Sabbagh L, Labrecque N, Sapieha P, Delisle JS. J Immunol. 2016 Nov 15;197(10):3927-3935.
- Leukocyte-specific protein 1 regulates T-cell migration in rheumatoid arthritis. Hwang SH, Jung SH, Lee S, Choi S, Yoo SA, Park JH, Hwang D, Shim SC, Sabbagh L, Kim KJ, Park SH, Cho CS, Kim BS, Leng L, Montgomery RR, Bucala R, Chung YJ, Kim WU. Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6535-43.
- Leukocyte-specific protein 1 links TNF receptor-associated factor 1 to survival signaling downstream of 4-1BB in T cells. Sabbagh L, Andreeva D, Laramée GD, Oussa NA, Lew D, Bisson N, Soumounou Y, Pawson T, Watts TH. J Leukoc Biol. 2013 May;93(5):713-721.
- TRAF1 phosphorylation on Serine 139 modulates NF-κB activity downstream of 4-1BB in T cells. Oussa NA, Soumounou Y, Sabbagh L. Biochem Biophys Res Commun. 2013 Mar 1;432(1):129-134.